Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
| Revenue (Most Recent Fiscal Year) | $358.71M |
| Net Income (Most Recent Fiscal Year) | $23.39M |
| PE Ratio (Current Year Earnings Estimate) | 10.02 |
| PE Ratio (Trailing 12 Months) | 12.32 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.38 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.75 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 5.79 |
| Pre-Tax Margin (Trailing 12 Months) | 17.71% |
| Net Margin (Trailing 12 Months) | 10.44% |
| Return on Equity (Trailing 12 Months) | 18.67% |
| Return on Assets (Trailing 12 Months) | 9.92% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.64 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.44 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.36 |
| Inventory Turnover (Trailing 12 Months) | 0.93 |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.34 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.77 |
| Earnings per Share (Most Recent Fiscal Year) | $2.37 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.31 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 63.02M |
| Free Float | 61.60M |
| Market Capitalization | $1.25B |
| Average Volume (Last 20 Days) | 0.82M |
| Beta (Past 60 Months) | 0.38 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.25% |
| Percentage Held By Institutions (Latest 13F Reports) | 99.12% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |